Autolus Reports Q3 Revenue of $41.2 Million, Raises 2026 Guidance
Autolus reported AUCATZYL net product revenue of $41.2 million for the third quarter ended September 30, 2026, up from $21.1 million a year earlier. The company expects full-year revenue to meet or exceed the upper end of its previous $150 million forecast.
Autolus Therapeutics announced its financial and operational results for the third quarter ended September 30, 2026. The company reported net product revenue of $41.2 million for its lead therapy, AUCATZYL, compared to $21.1 million in the same period last year. Driven by this performance, the company updated its full-year 2026 revenue guidance, now expecting AUCATZYL net product revenue to meet or exceed the upper end of its previous $150 million forecast. Additionally, Autolus reported a gross margin of 57% and stated that its current cash and projected revenues are expected to fund operations into the second quarter of 2028.